FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios | GenomeWeb

By Turna Ray

A long-awaited
draft guidance issued by the US Food and Drug Administration this week clarifies which in vitro diagnostics fall into the agency's definition of a companion test and outlines various drug/diagnostic codevelopment scenarios in which the agency would allow sponsors to market tests that don't have 510(k) clearance or premarket approval.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.